ICD-10-CM Code C43.51

Malignant melanoma of anal skin

Version 2020 Billable Code

Valid for Submission

C43.51 is a billable code used to specify a medical diagnosis of malignant melanoma of anal skin. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C43.51 might also be used to specify conditions or terms like malignant melanoma of anus or malignant melanoma of perianal skin or malignant melanoma of skin of anus or malignant melanoma of skin of perineum or primary malignant melanoma of anus.

ICD-10:C43.51
Short Description:Malignant melanoma of anal skin
Long Description:Malignant melanoma of anal skin

Tabular List of Diseases and Injuries

The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C43.51:

Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Malignant melanoma of anal margin
  • Malignant melanoma of perianal skin

Index to Diseases and Injuries

The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code C43.51 are found in the index:


Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Malignant melanoma of anus
  • Malignant melanoma of perianal skin
  • Malignant melanoma of skin of anus
  • Malignant melanoma of skin of perineum
  • Primary malignant melanoma of anus

Diagnostic Related Groups

The ICD-10 code C43.51 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2019 through 09/30/2020.

  • 595 - MAJOR SKIN DISORDERS WITH MCC
  • 596 - MAJOR SKIN DISORDERS WITHOUT MCC

Convert C43.51 to ICD-9

  • 172.5 - Malig melanoma trunk (Approximate Flag)

Code Classification

  • Neoplasms (C00–D48)
    • Melanoma and other malignant neoplasms of skin (C43-C44)
      • Malignant melanoma of skin (C43)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Information for Patients


Melanoma

Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking."

Thinking of "ABCDE" can help you remember what to watch for:

  • Asymmetry - the shape of one half does not match the other
  • Border - the edges are ragged, blurred or irregular
  • Color - the color is uneven and may include shades of black, brown and tan
  • Diameter - there is a change in size, usually an increase
  • Evolving - the mole has changed over the past few weeks or months

Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute


[Learn More]